The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of ...

Merck & Co, a leading healthcare giant, has seen its shares plummet by 30% over the past year. Investors generally view the ...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

AstraZeneca expects continued growth of its oncology medicines in the second half, particularly Tagrisso, Enhertu, and ...

Investment in American manufacturing is on the rise, with pharmaceutical giant Merck recently announcing a landmark $1 billion investment to establish a manufacturing plant in Wilmington, Delaware.

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...

Merck was a detractor despite "solid" first-quarter results, as it "disappointed the market" with a more subdued outlook for the rest of the year as it trimmed earlier guidance amid a slowdown in ...